Home > Annual Financials > SUPRIYA LIFESCIENCE

SUPRIYA LIFESCIENCE Financial Statement Analysis
[BOM: 543434|NSE : SUPRIYA]

The Revenues of SUPRIYA LIFESCIENCE have increased by 23.74% YoY .
The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has increased by 32.62 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

SUPRIYA LIFESCIENCE Last 5 Annual Financial Results
[BOM: 543434|NSE : SUPRIYA]

StandaloneMar2024
Mar2023
Mar2022
Mar2021
Mar2020
Revenues ₹570 Cr₹461 Cr₹530 Cr₹391 Cr₹312 Cr
Expenses ₹395 Cr₹332 Cr₹316 Cr₹218 Cr₹213 Cr
Operating Profit (Excl OI) ₹176 Cr₹128 Cr₹214 Cr₹173 Cr₹98 Cr
Other Income ₹11 Cr₹9.94 Cr₹7.58 Cr₹5.01 Cr₹11 Cr
Interest ₹5.15 Cr₹3.08 Cr₹4.20 Cr₹4.08 Cr₹6.85 Cr
Depreciation ₹16 Cr₹12 Cr₹10 Cr₹6.76 Cr₹6.38 Cr
Profit Before Tax ₹166 Cr₹123 Cr₹207 Cr₹167 Cr₹96 Cr
Profit After Tax ₹119 Cr₹90 Cr₹152 Cr₹124 Cr₹73 Cr
Earnings Per Share (Rs)₹14.80₹11.16₹18.86₹16.89₹50.15
PAT Margin (%)18.4117.4025.8028.6820.41
ROE(%)15.7313.6634.3459.1760.42
ROCE(%)22.3118.7143.3460.1249.67
Total Debt/Equity(x)0.000.020.030.260.55

Key Financials

Market Cap : ₹ 5,821.4 Cr
Revenue (TTM) : ₹ 625.0 Cr
Net Profit(TTM) : ₹ 157.5 Cr
EPS (TTM) : ₹ 19.6
P/E (TTM) : 37.0

Industry Peers & Returns1W1M1Y
SUPRIYA LIFESCIENCE -2.3% -7.1% 136.6%
SUN PHARMACEUTICAL INDUSTRIES -2% 2.1% 42.6%
CIPLA -2.6% -0.6% 17.9%
DR REDDYS LABORATORIES -2.7% 8.9% 14.2%
ZYDUS LIFESCIENCES -1% -1.7% 36.9%
DIVIS LABORATORIES -3.5% -3.4% 49.9%
MANKIND PHARMA 0.2% 10.2% 39.7%
TORRENT PHARMACEUTICALS -0.2% -0.3% 46.5%
LUPIN 0.3% 10.9% 69.7%


SUPRIYA LIFESCIENCE Revenues
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

23.74 %

5 Yr CAGR

16.31 %

Years Revenues % Change
Mar2024 ₹570 Cr
23.74
Mar2023 ₹461 Cr
-13.04
Mar2022 ₹530 Cr
35.49
Mar2021 ₹391 Cr
25.53
Mar2020 ₹312 Cr -


SUPRIYA LIFESCIENCE Operating Profit
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

36.79 %

5 Yr CAGR

15.60 %

Years Operating Profit % Change
Mar2024 ₹176 Cr
36.79
Mar2023 ₹128 Cr
-39.98
Mar2022 ₹214 Cr
23.59
Mar2021 ₹173 Cr
75.99
Mar2020 ₹98 Cr -

Operating Margins
Y-o-Y

10.51 %

5 Yr CAGR

-0.62 %

Years Operating Margin% % Change
Mar2024 30.8%
10.51
Mar2023 27.87%
-30.96
Mar2022 40.37%
-8.79
Mar2021 44.26%
40.20
Mar2020 31.57% -

SUPRIYA LIFESCIENCE Profit After Tax
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

32.56 %

5 Yr CAGR

12.87 %

Years Profit After Tax % Change
Mar2024 ₹119 Cr
32.56
Mar2023 ₹90 Cr
-40.81
Mar2022 ₹152 Cr
22.83
Mar2021 ₹124 Cr
68.38
Mar2020 ₹73 Cr -

PAT Margins
Y-o-Y

5.80 %

5 Yr CAGR

-2.55 %

Years PAT Margin(%) % Change
Mar2024 18.41 %
5.80
Mar2023 17.4 %
-32.56
Mar2022 25.8 %
-10.04
Mar2021 28.68 %
40.52
Mar2020 20.41 % -

SUPRIYA LIFESCIENCE Earnings Per Share (EPS)
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

32.62 %

5 Yr CAGR

-26.29 %

Years EPS % Change
Mar2024 ₹15
32.62
Mar2023 ₹11
-40.83
Mar2022 ₹19
11.66
Mar2021 ₹17
-66.32
Mar2020 ₹50 -

SUPRIYA LIFESCIENCE Return on Capital Employed (ROCE)
[BOM: 543434|NSE : SUPRIYA]

Y-o-Y

19.24 %

5 Yr CAGR

-18.13 %

Years ROCE % Change
Mar2024 22.31%
19.24
Mar2023 18.71%
-56.83
Mar2022 43.34%
-27.91
Mar2021 60.12%
21.04
Mar2020 49.67% -

SUPRIYA LIFESCIENCE Share Price vs Sensex

Current Share Price : ₹723.2
Current MarketCap: ₹ 5,821.4 Cr
Updated EOD on :Jan 06,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
SUPRIYA LIFESCIENCE

-2.3%

-7.1%

136.6%

SENSEX

-0.4%

-3.7%

7.9%

SUPRIYA LIFESCIENCE related INDICES

BSE Indices1W1M1Y
S&P BSE ALLCAP -0.3% -3.5% 35.8%
S&P BSE HEALTHCARE -0.5% 1.2% 41.9%
S&P BSE SMALL CAP -0.8% -4% 26.4%
S&P BSE MIDSMALLCAP -1% -3.7% 25.1%
No NSE index found

You may also like the below Video Courses


FAQ about SUPRIYA LIFESCIENCE Financials


How the annual revenues of SUPRIYA LIFESCIENCE have changed ?

The Revenues of SUPRIYA LIFESCIENCE have increased by 23.74% YoY .

How the Earnings per Share (EPS) of SUPRIYA LIFESCIENCE have changed?

The Earnings Per Share (EPS) of SUPRIYA LIFESCIENCE has increased by 32.62 % YoY .